PROGRESSION‐FREE SURVIVAL SUBGROUPS IN
PAZOPANIB TRIAL
Baseline factor
Hazard ratio (95% CI)
Primary analysis
MSKCC risk: favourable
MSKCC risk: intermediate
Female
Male
Age <65 years
Age
`LH
ECOG performance status 0
0.2
0.4
0.8
1.0
0.6
1.2
ECOG performance status 1
Favours pazopanib Favours placebo
p<0.001 by log-rank test for all
Sternberg CN, et al. J Clin Oncol 2010;28:1061‐8
